Department of Psychiatry, Columbia University College of Physicians and Surgeons, 1051 Riverside Drive, New York, NY 10032, United States.
Schizophr Res. 2011 Aug;130(1-3):47-52. doi: 10.1016/j.schres.2011.04.012. Epub 2011 May 10.
Research participants must have adequate consent-related abilities to provide informed consent at the time of study enrollment. We sought to determine if research participants with schizophrenia maintain adequate consent-related abilities during a longitudinal study. If participants lose abilities during a trial they may not be able to judge and protect their interests. If reduced abilities are common or can be predicted, special protections can be targeted appropriately.
We examined longitudinal consent-related abilities of participants in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study using the MacArthur Competence Assessment Tool-Clinical Research (MacCAT-CR) at protocol-specified times over 18 months.
Of 1158 research participants in this analysis, most (n=650, 56%) had a stable pattern of MacCAT-CR Understanding scores, 235 (20%) improved substantially with no evidence of decline, 273 (24%) had at least one assessment with substantial worsening. During the course of the trial, 43 (4%) fell below the initial threshold for adequate capacity, which was predicted by lower Understanding scores, more severe positive symptoms, and poorer neurocognitive functioning at baseline, and by increases in negative symptoms and deteriorating global status.
Most participants in this long-term study had stable or improved consent-related abilities, but almost one-fourth experienced substantial worsening and 4% of participants fell below the study's capacity threshold for enrollment. Clinical investigators should monitor with special care individuals with marginal capacity or higher levels of psychotic symptoms at study entry and those who exhibit clinical worsening during a study.
研究参与者必须具备充分的与同意相关的能力,以便在研究入组时提供知情同意。我们试图确定患有精神分裂症的研究参与者在纵向研究期间是否保持充分的与同意相关的能力。如果参与者在试验期间丧失能力,他们可能无法判断和保护自己的利益。如果能力下降较为普遍或可预测,则可相应地提供特殊保护。
我们使用 MacArthur 能力评估工具-临床研究(MacCAT-CR),在 18 个月的时间内,按方案规定的时间,检查了参与临床抗精神病药物干预有效性试验(CATIE)精神分裂症研究的参与者的纵向与同意相关的能力。
在本分析中的 1158 名研究参与者中,大多数(n=650,56%)的 MacCAT-CR 理解评分具有稳定的模式,235 名(20%)有显著提高,没有下降的迹象,273 名(24%)至少有一次评估显示有显著恶化。在试验过程中,有 43 名(4%)的参与者低于最初的充分能力阈值,这是由较低的理解评分、更严重的阳性症状、基线时较差的神经认知功能以及阴性症状的增加和整体状况的恶化预测的。
在这项长期研究中,大多数参与者的与同意相关的能力稳定或有所改善,但近四分之一的参与者的能力显著恶化,4%的参与者低于研究的入组能力阈值。临床研究者应特别关注那些在研究入组时具有边缘能力或更高水平的精神病症状以及在研究过程中表现出临床恶化的个体。